TRIlogy-5

A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide

Near Add Your Location

New York University Langone Medical Center
Laura and Isaac Perlmutter Cancer Center
New York, NY
  • Accepting patients
Winship Cancer Institute
Emory University
Atlanta, GA
  • Accepting patients
Highlands Oncology Group
Springdale, AR
  • Accepting patients
Valkyrie Clinical Trials
Los Angeles, CA
  • Accepting patients
Astera Cancer Care
East Brunswick, NJ
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.